Investigating how a specific potassium channel affects brain immune cells in Parkinson's disease.
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis
This study is looking at how a specific protein channel in brain immune cells, called KCa3.1, affects the way these cells behave in Parkinson's disease, with the hope of finding new treatments to help manage the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10927205 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of KCa3.1, a calcium-activated potassium channel, in the function of microglia, which are immune cells in the brain. The study aims to uncover how microglia contribute to the progression of Parkinson's disease through neuroinflammation and the aggregation of alpha-synuclein, a protein linked to the disease. By exploring the cellular mechanisms that regulate microglial responses, the research seeks to identify potential new therapies that could modulate immune responses in Parkinson's patients. The approach includes both laboratory studies using preclinical models and analysis of postmortem brain tissues from individuals with Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Parkinson's disease.
Not a fit: Patients with Parkinson's disease who are not responsive to immune modulation therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunomodulatory therapies that improve outcomes for patients with Parkinson's disease.
How similar studies have performed: Other research has shown promising results in targeting microglial function for neurodegenerative diseases, indicating that this approach may be viable.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Kanthasamy, Arthi — University of Georgia
- Study coordinator: Kanthasamy, Arthi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.